Physiological Systems and Anatomical Regions, Introduction

Codes in table 3E0

Every code is billable. The 7 characters spell out section, body system, operation, body part, approach, device and qualifier.

• 3E00X05Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach
• 3E00X0MIntroduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach
• 3E00X28Introduction of Oxazolidinones into Skin and Mucous Membranes, External Approach
• 3E00X29Introduction of Other Anti-infective into Skin and Mucous Membranes, External Approach
• 3E00X3ZIntroduction of Anti-inflammatory into Skin and Mucous Membranes, External Approach
• 3E00X4ZIntroduction of Serum, Toxoid and Vaccine into Skin and Mucous Membranes, External Approach
• 3E00XBZIntroduction of Anesthetic Agent into Skin and Mucous Membranes, External Approach
• 3E00XGCIntroduction of Other Therapeutic Substance into Skin and Mucous Membranes, External Approach
• 3E00XGFIntroduction of Other Enzymatic/Chemical Agent into Skin and Mucous Membranes, External Approach
• 3E00XKZIntroduction of Other Diagnostic Substance into Skin and Mucous Membranes, External Approach
• 3E00XMZIntroduction of Pigment into Skin and Mucous Membranes, External Approach
• 3E00XNZIntroduction of Analgesics, Hypnotics, Sedatives into Skin and Mucous Membranes, External Approach
• 3E00XTZIntroduction of Destructive Agent into Skin and Mucous Membranes, External Approach
• 3E0102AIntroduction of Anti-Infective Envelope into Subcutaneous Tissue, Open Approach
• 3E01305Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach
• 3E0130MIntroduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach
• 3E01328Introduction of Oxazolidinones into Subcutaneous Tissue, Percutaneous Approach
• 3E01329Introduction of Other Anti-infective into Subcutaneous Tissue, Percutaneous Approach
• 3E0132AIntroduction of Anti-Infective Envelope into Subcutaneous Tissue, Percutaneous Approach
• 3E0133ZIntroduction of Anti-inflammatory into Subcutaneous Tissue, Percutaneous Approach
• 3E01340Introduction of Influenza Vaccine into Subcutaneous Tissue, Percutaneous Approach
• 3E0134ZIntroduction of Serum, Toxoid and Vaccine into Subcutaneous Tissue, Percutaneous Approach
• 3E0136ZIntroduction of Nutritional Substance into Subcutaneous Tissue, Percutaneous Approach
• 3E0137ZIntroduction of Electrolytic and Water Balance Substance into Subcutaneous Tissue, Percutaneous Approach
• 3E013BZIntroduction of Anesthetic Agent into Subcutaneous Tissue, Percutaneous Approach
• 3E013GCIntroduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach
• 3E013HZIntroduction of Radioactive Substance into Subcutaneous Tissue, Percutaneous Approach
• 3E013KZIntroduction of Other Diagnostic Substance into Subcutaneous Tissue, Percutaneous Approach
• 3E013NZIntroduction of Analgesics, Hypnotics, Sedatives into Subcutaneous Tissue, Percutaneous Approach
• 3E013TZIntroduction of Destructive Agent into Subcutaneous Tissue, Percutaneous Approach
• 3E013VGIntroduction of Insulin into Subcutaneous Tissue, Percutaneous Approach
• 3E013VJIntroduction of Other Hormone into Subcutaneous Tissue, Percutaneous Approach
• 3E01XGFIntroduction of Other Enzymatic/Chemical Agent into Subcutaneous Tissue, External Approach
• 3E02305Introduction of Other Antineoplastic into Muscle, Percutaneous Approach
• 3E0230MIntroduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach
• 3E02328Introduction of Oxazolidinones into Muscle, Percutaneous Approach
• 3E02329Introduction of Other Anti-infective into Muscle, Percutaneous Approach
• 3E0233ZIntroduction of Anti-inflammatory into Muscle, Percutaneous Approach
• 3E02340Introduction of Influenza Vaccine into Muscle, Percutaneous Approach
• 3E0234ZIntroduction of Serum, Toxoid and Vaccine into Muscle, Percutaneous Approach
• 3E0236ZIntroduction of Nutritional Substance into Muscle, Percutaneous Approach
• 3E0237ZIntroduction of Electrolytic and Water Balance Substance into Muscle, Percutaneous Approach
• 3E023BZIntroduction of Anesthetic Agent into Muscle, Percutaneous Approach
• 3E023GCIntroduction of Other Therapeutic Substance into Muscle, Percutaneous Approach
• 3E023HZIntroduction of Radioactive Substance into Muscle, Percutaneous Approach
• 3E023KZIntroduction of Other Diagnostic Substance into Muscle, Percutaneous Approach
• 3E023NZIntroduction of Analgesics, Hypnotics, Sedatives into Muscle, Percutaneous Approach
• 3E023TZIntroduction of Destructive Agent into Muscle, Percutaneous Approach
• 3E03002Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach
• 3E03003Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach
• 3E03005Introduction of Other Antineoplastic into Peripheral Vein, Open Approach
• 3E0300MIntroduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach
• 3E0300PIntroduction of Clofarabine into Peripheral Vein, Open Approach
• 3E03016Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Open
• 3E03017Introduction of Other Thrombolytic into Peripheral Vein, Open Approach
• 3E03028Introduction of Oxazolidinones into Peripheral Vein, Open Approach
• 3E03029Introduction of Other Anti-infective into Peripheral Vein, Open Approach
• 3E0303ZIntroduction of Anti-inflammatory into Peripheral Vein, Open Approach
• 3E0304ZIntroduction of Serum, Toxoid and Vaccine into Peripheral Vein, Open Approach
• 3E0306ZIntroduction of Nutritional Substance into Peripheral Vein, Open Approach
• 3E0307ZIntroduction of Electrolytic and Water Balance Substance into Peripheral Vein, Open Approach
• 3E030FZIntroduction of Intracirculatory Anesthetic into Peripheral Vein, Open Approach
• 3E030GCIntroduction of Other Therapeutic Substance into Peripheral Vein, Open Approach
• 3E030GNIntroduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach
• 3E030HZIntroduction of Radioactive Substance into Peripheral Vein, Open Approach
• 3E030KZIntroduction of Other Diagnostic Substance into Peripheral Vein, Open Approach
• 3E030NZIntroduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Open Approach
• 3E030PZIntroduction of Platelet Inhibitor into Peripheral Vein, Open Approach
• 3E030RZIntroduction of Antiarrhythmic into Peripheral Vein, Open Approach
• 3E030TZIntroduction of Destructive Agent into Peripheral Vein, Open Approach
• 3E030U0Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Open Approach
• 3E030U1Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach
• 3E030VGIntroduction of Insulin into Peripheral Vein, Open Approach
• 3E030VHIntroduction of Human B-type Natriuretic Peptide into Peripheral Vein, Open Approach
• 3E030VJIntroduction of Other Hormone into Peripheral Vein, Open Approach
• 3E030WKIntroduction of Immunostimulator into Peripheral Vein, Open
• 3E030WLIntroduction of Immunosuppressive into Peripheral Vein, Open
• 3E030XZIntroduction of Vasopressor into Peripheral Vein, Open Approach
• 3E03302Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
• 3E03303Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
• 3E03305Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach
• 3E0330MIntroduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach
• 3E0330PIntroduction of Clofarabine into Peripheral Vein, Percutaneous Approach
• 3E03316Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Percutaneous
• 3E03317Introduction of Other Thrombolytic into Peripheral Vein, Percutaneous Approach
• 3E03328Introduction of Oxazolidinones into Peripheral Vein, Percutaneous Approach
• 3E03329Introduction of Other Anti-infective into Peripheral Vein, Percutaneous Approach
• 3E0333ZIntroduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach
• 3E0334ZIntroduction of Serum, Toxoid and Vaccine into Peripheral Vein, Percutaneous Approach
• 3E0336ZIntroduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach
• 3E0337ZIntroduction of Electrolytic and Water Balance Substance into Peripheral Vein, Percutaneous Approach
• 3E033AZIntroduction of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach
• 3E033FZIntroduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach
• 3E033GCIntroduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach
• 3E033GNIntroduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Percutaneous Approach
• 3E033GQIntroduction of Glucarpidase into Peripheral Vein, Percutaneous Approach
• 3E033GRIntroduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein, Percutaneous Approach
• 3E033HZIntroduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach
• 3E033KZIntroduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach
• 3E033NZIntroduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach
• 3E033PZIntroduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach
• 3E033RZIntroduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach
• 3E033TZIntroduction of Destructive Agent into Peripheral Vein, Percutaneous Approach
• 3E033U0Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach
• 3E033U1Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach
• 3E033VGIntroduction of Insulin into Peripheral Vein, Percutaneous Approach
• 3E033VHIntroduction of Human B-type Natriuretic Peptide into Peripheral Vein, Percutaneous Approach
• 3E033VJIntroduction of Other Hormone into Peripheral Vein, Percutaneous Approach
• 3E033WKIntroduction of Immunostimulator into Peripheral Vein, Percutaneous
• 3E033WLIntroduction of Immunosuppressive into Peripheral Vein, Percutaneous
• 3E033XZIntroduction of Vasopressor into Peripheral Vein, Percutaneous Approach
• 3E04002Introduction of High-dose Interleukin-2 into Central Vein, Open Approach
• 3E04003Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach
• 3E04005Introduction of Other Antineoplastic into Central Vein, Open Approach
• 3E0400MIntroduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach
• 3E0400PIntroduction of Clofarabine into Central Vein, Open Approach
• 3E04016Introduction of Recombinant Human-activated Protein C into Central Vein, Open
• 3E04017Introduction of Other Thrombolytic into Central Vein, Open Approach
• 3E04028Introduction of Oxazolidinones into Central Vein, Open Approach
• 3E04029Introduction of Other Anti-infective into Central Vein, Open Approach
• 3E0403ZIntroduction of Anti-inflammatory into Central Vein, Open Approach
• 3E0404ZIntroduction of Serum, Toxoid and Vaccine into Central Vein, Open Approach
• 3E0406ZIntroduction of Nutritional Substance into Central Vein, Open Approach
• 3E0407ZIntroduction of Electrolytic and Water Balance Substance into Central Vein, Open Approach
• 3E040FZIntroduction of Intracirculatory Anesthetic into Central Vein, Open Approach
• 3E040GCIntroduction of Other Therapeutic Substance into Central Vein, Open Approach
• 3E040GNIntroduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach
• 3E040HZIntroduction of Radioactive Substance into Central Vein, Open Approach
• 3E040KZIntroduction of Other Diagnostic Substance into Central Vein, Open Approach
• 3E040NZIntroduction of Analgesics, Hypnotics, Sedatives into Central Vein, Open Approach
• 3E040PZIntroduction of Platelet Inhibitor into Central Vein, Open Approach
• 3E040RZIntroduction of Antiarrhythmic into Central Vein, Open Approach
• 3E040TZIntroduction of Destructive Agent into Central Vein, Open Approach
• 3E040VGIntroduction of Insulin into Central Vein, Open Approach
• 3E040VHIntroduction of Human B-type Natriuretic Peptide into Central Vein, Open Approach
• 3E040VJIntroduction of Other Hormone into Central Vein, Open Approach
• 3E040WKIntroduction of Immunostimulator into Central Vein, Open
• 3E040WLIntroduction of Immunosuppressive into Central Vein, Open
• 3E040XZIntroduction of Vasopressor into Central Vein, Open Approach
• 3E04302Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach
• 3E04303Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach
• 3E04305Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach
• 3E0430MIntroduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach
• 3E0430PIntroduction of Clofarabine into Central Vein, Percutaneous Approach
• 3E04316Introduction of Recombinant Human-activated Protein C into Central Vein, Percutaneous
• 3E04317Introduction of Other Thrombolytic into Central Vein, Percutaneous Approach
• 3E04328Introduction of Oxazolidinones into Central Vein, Percutaneous Approach
• 3E04329Introduction of Other Anti-infective into Central Vein, Percutaneous Approach
• 3E0433ZIntroduction of Anti-inflammatory into Central Vein, Percutaneous Approach
• 3E0434ZIntroduction of Serum, Toxoid and Vaccine into Central Vein, Percutaneous Approach
• 3E0436ZIntroduction of Nutritional Substance into Central Vein, Percutaneous Approach
• 3E0437ZIntroduction of Electrolytic and Water Balance Substance into Central Vein, Percutaneous Approach
• 3E043AZIntroduction of Embryonic Stem Cells into Central Vein, Percutaneous Approach
• 3E043FZIntroduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach
• 3E043GCIntroduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach
• 3E043GNIntroduction of Blood Brain Barrier Disruption Substance into Central Vein, Percutaneous Approach
• 3E043GQIntroduction of Glucarpidase into Central Vein, Percutaneous Approach
• 3E043GRIntroduction of Other Therapeutic Monoclonal Antibody into Central Vein, Percutaneous Approach
• 3E043HZIntroduction of Radioactive Substance into Central Vein, Percutaneous Approach
• 3E043KZIntroduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach
• 3E043NZIntroduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach
• 3E043PZIntroduction of Platelet Inhibitor into Central Vein, Percutaneous Approach
• 3E043RZIntroduction of Antiarrhythmic into Central Vein, Percutaneous Approach
• 3E043TZIntroduction of Destructive Agent into Central Vein, Percutaneous Approach
• 3E043VGIntroduction of Insulin into Central Vein, Percutaneous Approach
• 3E043VHIntroduction of Human B-type Natriuretic Peptide into Central Vein, Percutaneous Approach
• 3E043VJIntroduction of Other Hormone into Central Vein, Percutaneous Approach
• 3E043WKIntroduction of Immunostimulator into Central Vein, Percutaneous
• 3E043WLIntroduction of Immunosuppressive into Central Vein, Percutaneous
• 3E043XZIntroduction of Vasopressor into Central Vein, Percutaneous Approach
• 3E05002Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach
• 3E05003Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach
• 3E05005Introduction of Other Antineoplastic into Peripheral Artery, Open Approach
• 3E0500MIntroduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach
• 3E0500PIntroduction of Clofarabine into Peripheral Artery, Open Approach
• 3E05016Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Open
• 3E05017Introduction of Other Thrombolytic into Peripheral Artery, Open Approach
• 3E05028Introduction of Oxazolidinones into Peripheral Artery, Open Approach
• 3E05029Introduction of Other Anti-infective into Peripheral Artery, Open Approach
• 3E0503ZIntroduction of Anti-inflammatory into Peripheral Artery, Open Approach
• 3E0504ZIntroduction of Serum, Toxoid and Vaccine into Peripheral Artery, Open Approach
• 3E0506ZIntroduction of Nutritional Substance into Peripheral Artery, Open Approach
• 3E0507ZIntroduction of Electrolytic and Water Balance Substance into Peripheral Artery, Open Approach
• 3E050FZIntroduction of Intracirculatory Anesthetic into Peripheral Artery, Open Approach
• 3E050GCIntroduction of Other Therapeutic Substance into Peripheral Artery, Open Approach
• 3E050GNIntroduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach
• 3E050HZIntroduction of Radioactive Substance into Peripheral Artery, Open Approach
• 3E050KZIntroduction of Other Diagnostic Substance into Peripheral Artery, Open Approach
• 3E050NZIntroduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Open Approach
• 3E050PZIntroduction of Platelet Inhibitor into Peripheral Artery, Open Approach
• 3E050RZIntroduction of Antiarrhythmic into Peripheral Artery, Open Approach
• 3E050TZIntroduction of Destructive Agent into Peripheral Artery, Open Approach
• 3E050VGIntroduction of Insulin into Peripheral Artery, Open Approach
• 3E050VHIntroduction of Human B-type Natriuretic Peptide into Peripheral Artery, Open Approach
• 3E050VJIntroduction of Other Hormone into Peripheral Artery, Open Approach
• 3E050WKIntroduction of Immunostimulator into Peripheral Artery, Open
• 3E050WLIntroduction of Immunosuppressive into Peripheral Artery, Open
• 3E050XZIntroduction of Vasopressor into Peripheral Artery, Open Approach
• 3E05302Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
• 3E05303Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach
• 3E05305Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach
• 3E0530MIntroduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach
• 3E0530PIntroduction of Clofarabine into Peripheral Artery, Percutaneous Approach
• 3E05316Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Percutaneous
• 3E05317Introduction of Other Thrombolytic into Peripheral Artery, Percutaneous Approach
• 3E05328Introduction of Oxazolidinones into Peripheral Artery, Percutaneous Approach
• 3E05329Introduction of Other Anti-infective into Peripheral Artery, Percutaneous Approach
• 3E0533ZIntroduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach
• 3E0534ZIntroduction of Serum, Toxoid and Vaccine into Peripheral Artery, Percutaneous Approach
• 3E0536ZIntroduction of Nutritional Substance into Peripheral Artery, Percutaneous Approach
• 3E0537ZIntroduction of Electrolytic and Water Balance Substance into Peripheral Artery, Percutaneous Approach
• 3E053FZIntroduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach
• 3E053GCIntroduction of Other Therapeutic Substance into Peripheral Artery, Percutaneous Approach
• 3E053GNIntroduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Percutaneous Approach
• 3E053HZIntroduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach
• 3E053KZIntroduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach
• 3E053NZIntroduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Percutaneous Approach
• 3E053PZIntroduction of Platelet Inhibitor into Peripheral Artery, Percutaneous Approach
• 3E053RZIntroduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach
• 3E053TZIntroduction of Destructive Agent into Peripheral Artery, Percutaneous Approach
• 3E053VGIntroduction of Insulin into Peripheral Artery, Percutaneous Approach
• 3E053VHIntroduction of Human B-type Natriuretic Peptide into Peripheral Artery, Percutaneous Approach
• 3E053VJIntroduction of Other Hormone into Peripheral Artery, Percutaneous Approach
• 3E053WKIntroduction of Immunostimulator into Peripheral Artery, Percutaneous
• 3E053WLIntroduction of Immunosuppressive into Peripheral Artery, Percutaneous
• 3E053XZIntroduction of Vasopressor into Peripheral Artery, Percutaneous Approach
• 3E06002Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
• 3E06003Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach
• 3E06005Introduction of Other Antineoplastic into Central Artery, Open Approach
• 3E0600MIntroduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach
• 3E0600PIntroduction of Clofarabine into Central Artery, Open Approach
• 3E06016Introduction of Recombinant Human-activated Protein C into Central Artery, Open
• 3E06017Introduction of Other Thrombolytic into Central Artery, Open Approach
• 3E06028Introduction of Oxazolidinones into Central Artery, Open Approach
• 3E06029Introduction of Other Anti-infective into Central Artery, Open Approach
• 3E0603ZIntroduction of Anti-inflammatory into Central Artery, Open Approach
• 3E0604ZIntroduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach
• 3E0606ZIntroduction of Nutritional Substance into Central Artery, Open Approach
• 3E0607ZIntroduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach
• 3E060FZIntroduction of Intracirculatory Anesthetic into Central Artery, Open Approach
• 3E060GCIntroduction of Other Therapeutic Substance into Central Artery, Open Approach
• 3E060GNIntroduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach
• 3E060HZIntroduction of Radioactive Substance into Central Artery, Open Approach
• 3E060KZIntroduction of Other Diagnostic Substance into Central Artery, Open Approach
• 3E060NZIntroduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach
• 3E060PZIntroduction of Platelet Inhibitor into Central Artery, Open Approach
• 3E060RZIntroduction of Antiarrhythmic into Central Artery, Open Approach
• 3E060TZIntroduction of Destructive Agent into Central Artery, Open Approach
• 3E060VGIntroduction of Insulin into Central Artery, Open Approach
• 3E060VHIntroduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach
• 3E060VJIntroduction of Other Hormone into Central Artery, Open Approach
• 3E060WKIntroduction of Immunostimulator into Central Artery, Open
• 3E060WLIntroduction of Immunosuppressive into Central Artery, Open
• 3E060XZIntroduction of Vasopressor into Central Artery, Open Approach
• 3E06302Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach
• 3E06303Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach
• 3E06305Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach
• 3E0630MIntroduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach
• 3E0630PIntroduction of Clofarabine into Central Artery, Percutaneous Approach
• 3E06316Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous
• 3E06317Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach
• 3E06328Introduction of Oxazolidinones into Central Artery, Percutaneous Approach
• 3E06329Introduction of Other Anti-infective into Central Artery, Percutaneous Approach
• 3E0633ZIntroduction of Anti-inflammatory into Central Artery, Percutaneous Approach
• 3E0634ZIntroduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach
• 3E0636ZIntroduction of Nutritional Substance into Central Artery, Percutaneous Approach
• 3E0637ZIntroduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach
• 3E063FZIntroduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach
• 3E063GCIntroduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach
• 3E063GNIntroduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach
• 3E063HZIntroduction of Radioactive Substance into Central Artery, Percutaneous Approach
• 3E063KZIntroduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach
• 3E063NZIntroduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach
• 3E063PZIntroduction of Platelet Inhibitor into Central Artery, Percutaneous Approach
• 3E063RZIntroduction of Antiarrhythmic into Central Artery, Percutaneous Approach
• 3E063TZIntroduction of Destructive Agent into Central Artery, Percutaneous Approach
• 3E063VGIntroduction of Insulin into Central Artery, Percutaneous Approach
• 3E063VHIntroduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach
• 3E063VJIntroduction of Other Hormone into Central Artery, Percutaneous Approach
• 3E063WKIntroduction of Immunostimulator into Central Artery, Percutaneous
• 3E063WLIntroduction of Immunosuppressive into Central Artery, Percutaneous
• 3E063XZIntroduction of Vasopressor into Central Artery, Percutaneous Approach
• 3E07016Introduction of Recombinant Human-activated Protein C into Coronary Artery, Open
• 3E07017Introduction of Other Thrombolytic into Coronary Artery, Open Approach
• 3E070GCIntroduction of Other Therapeutic Substance into Coronary Artery, Open Approach
• 3E070KZIntroduction of Other Diagnostic Substance into Coronary Artery, Open Approach
• 3E070PZIntroduction of Platelet Inhibitor into Coronary Artery, Open Approach
• 3E07316Introduction of Recombinant Human-activated Protein C into Coronary Artery, Percutaneous
• 3E07317Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach
• 3E073GCIntroduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Approach
• 3E073KZIntroduction of Other Diagnostic Substance into Coronary Artery, Percutaneous Approach
• 3E073PZIntroduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach
• 3E074GCIntroduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Endoscopic Approach
• 3E08016Introduction of Recombinant Human-activated Protein C into Heart, Open
• 3E08017Introduction of Other Thrombolytic into Heart, Open Approach
• 3E080GCIntroduction of Other Therapeutic Substance into Heart, Open Approach
• 3E080KZIntroduction of Other Diagnostic Substance into Heart, Open Approach
• 3E080PZIntroduction of Platelet Inhibitor into Heart, Open Approach
• 3E08316Introduction of Recombinant Human-activated Protein C into Heart, Percutaneous
• 3E08317Introduction of Other Thrombolytic into Heart, Percutaneous Approach
• 3E083GCIntroduction of Other Therapeutic Substance into Heart, Percutaneous Approach
• 3E083KZIntroduction of Other Diagnostic Substance into Heart, Percutaneous Approach
• 3E083PZIntroduction of Platelet Inhibitor into Heart, Percutaneous Approach
• 3E084GCIntroduction of Other Therapeutic Substance into Heart, Percutaneous Endoscopic Approach
• 3E09305Introduction of Other Antineoplastic into Nose, Percutaneous Approach
• 3E0930MIntroduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach
• 3E09328Introduction of Oxazolidinones into Nose, Percutaneous Approach
• 3E09329Introduction of Other Anti-infective into Nose, Percutaneous Approach
• 3E0933ZIntroduction of Anti-inflammatory into Nose, Percutaneous Approach
• 3E0934ZIntroduction of Serum, Toxoid and Vaccine into Nose, Percutaneous Approach
• 3E093BZIntroduction of Anesthetic Agent into Nose, Percutaneous Approach
• 3E093GCIntroduction of Other Therapeutic Substance into Nose, Percutaneous Approach
• 3E093HZIntroduction of Radioactive Substance into Nose, Percutaneous Approach
• 3E093KZIntroduction of Other Diagnostic Substance into Nose, Percutaneous Approach
• 3E093NZIntroduction of Analgesics, Hypnotics, Sedatives into Nose, Percutaneous Approach
• 3E093TZIntroduction of Destructive Agent into Nose, Percutaneous Approach
• 3E09705Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening
• 3E0970MIntroduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening
• 3E09728Introduction of Oxazolidinones into Nose, Via Natural or Artificial Opening
• 3E09729Introduction of Other Anti-infective into Nose, Via Natural or Artificial Opening
• 3E0973ZIntroduction of Anti-inflammatory into Nose, Via Natural or Artificial Opening
• 3E0974ZIntroduction of Serum, Toxoid and Vaccine into Nose, Via Natural or Artificial Opening
• 3E097BZIntroduction of Anesthetic Agent into Nose, Via Natural or Artificial Opening
• 3E097GCIntroduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening
• 3E097HZIntroduction of Radioactive Substance into Nose, Via Natural or Artificial Opening
• 3E097KZIntroduction of Other Diagnostic Substance into Nose, Via Natural or Artificial Opening
• 3E097NZIntroduction of Analgesics, Hypnotics, Sedatives into Nose, Via Natural or Artificial Opening
• 3E097TZIntroduction of Destructive Agent into Nose, Via Natural or Artificial Opening
• 3E09X05Introduction of Other Antineoplastic into Nose, External Approach
• 3E09X0MIntroduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach
• 3E09X28Introduction of Oxazolidinones into Nose, External Approach
• 3E09X29Introduction of Other Anti-infective into Nose, External Approach
• 3E09X3ZIntroduction of Anti-inflammatory into Nose, External Approach
• 3E09X4ZIntroduction of Serum, Toxoid and Vaccine into Nose, External Approach
• 3E09XBZIntroduction of Anesthetic Agent into Nose, External Approach
• 3E09XGCIntroduction of Other Therapeutic Substance into Nose, External Approach
• 3E09XHZIntroduction of Radioactive Substance into Nose, External Approach
• 3E09XKZIntroduction of Other Diagnostic Substance into Nose, External Approach
• 3E09XNZIntroduction of Analgesics, Hypnotics, Sedatives into Nose, External Approach
• 3E09XTZIntroduction of Destructive Agent into Nose, External Approach
• 3E0A305Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach
• 3E0A30MIntroduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach
• 3E0A3GCIntroduction of Other Therapeutic Substance into Bone Marrow, Percutaneous Approach
• 3E0B304Introduction of Liquid Brachytherapy Radioisotope into Ear, Percutaneous Approach
• 3E0B305Introduction of Other Antineoplastic into Ear, Percutaneous Approach
• 3E0B30MIntroduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach
• 3E0B328Introduction of Oxazolidinones into Ear, Percutaneous Approach
• 3E0B329Introduction of Other Anti-infective into Ear, Percutaneous Approach
• 3E0B33ZIntroduction of Anti-inflammatory into Ear, Percutaneous Approach
• 3E0B3BZIntroduction of Anesthetic Agent into Ear, Percutaneous Approach
• 3E0B3GCIntroduction of Other Therapeutic Substance into Ear, Percutaneous Approach
• 3E0B3HZIntroduction of Radioactive Substance into Ear, Percutaneous Approach
• 3E0B3KZIntroduction of Other Diagnostic Substance into Ear, Percutaneous Approach
• 3E0B3NZIntroduction of Analgesics, Hypnotics, Sedatives into Ear, Percutaneous Approach
• 3E0B3TZIntroduction of Destructive Agent into Ear, Percutaneous Approach
• 3E0B704Introduction of Liquid Brachytherapy Radioisotope into Ear, Via Natural or Artificial Opening
• 3E0B705Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening
• 3E0B70MIntroduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening
• 3E0B728Introduction of Oxazolidinones into Ear, Via Natural or Artificial Opening
• 3E0B729Introduction of Other Anti-infective into Ear, Via Natural or Artificial Opening
• 3E0B73ZIntroduction of Anti-inflammatory into Ear, Via Natural or Artificial Opening
• 3E0B7BZIntroduction of Anesthetic Agent into Ear, Via Natural or Artificial Opening
• 3E0B7GCIntroduction of Other Therapeutic Substance into Ear, Via Natural or Artificial Opening
• 3E0B7HZIntroduction of Radioactive Substance into Ear, Via Natural or Artificial Opening
• 3E0B7KZIntroduction of Other Diagnostic Substance into Ear, Via Natural or Artificial Opening
• 3E0B7NZIntroduction of Analgesics, Hypnotics, Sedatives into Ear, Via Natural or Artificial Opening
• 3E0B7TZIntroduction of Destructive Agent into Ear, Via Natural or Artificial Opening
• 3E0BX04Introduction of Liquid Brachytherapy Radioisotope into Ear, External Approach
• 3E0BX05Introduction of Other Antineoplastic into Ear, External Approach
• 3E0BX0MIntroduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach
• 3E0BX28Introduction of Oxazolidinones into Ear, External Approach
• 3E0BX29Introduction of Other Anti-infective into Ear, External Approach
• 3E0BX3ZIntroduction of Anti-inflammatory into Ear, External Approach
• 3E0BXBZIntroduction of Anesthetic Agent into Ear, External Approach
• 3E0BXGCIntroduction of Other Therapeutic Substance into Ear, External Approach
• 3E0BXHZIntroduction of Radioactive Substance into Ear, External Approach
• 3E0BXKZIntroduction of Other Diagnostic Substance into Ear, External Approach
• 3E0BXNZIntroduction of Analgesics, Hypnotics, Sedatives into Ear, External Approach
• 3E0BXTZIntroduction of Destructive Agent into Ear, External Approach
• 3E0C304Introduction of Liquid Brachytherapy Radioisotope into Eye, Percutaneous Approach
• 3E0C305Introduction of Other Antineoplastic into Eye, Percutaneous Approach
• 3E0C30MIntroduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach
• 3E0C328Introduction of Oxazolidinones into Eye, Percutaneous Approach
• 3E0C329Introduction of Other Anti-infective into Eye, Percutaneous Approach
• 3E0C33ZIntroduction of Anti-inflammatory into Eye, Percutaneous Approach
• 3E0C3BZIntroduction of Anesthetic Agent into Eye, Percutaneous Approach
• 3E0C3GCIntroduction of Other Therapeutic Substance into Eye, Percutaneous Approach
• 3E0C3HZIntroduction of Radioactive Substance into Eye, Percutaneous Approach
• 3E0C3KZIntroduction of Other Diagnostic Substance into Eye, Percutaneous Approach
• 3E0C3MZIntroduction of Pigment into Eye, Percutaneous Approach
• 3E0C3NZIntroduction of Analgesics, Hypnotics, Sedatives into Eye, Percutaneous Approach
• 3E0C3SFIntroduction of Other Gas into Eye, Percutaneous Approach
• 3E0C3TZIntroduction of Destructive Agent into Eye, Percutaneous Approach
• 3E0C704Introduction of Liquid Brachytherapy Radioisotope into Eye, Via Natural or Artificial Opening
• 3E0C705Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening
• 3E0C70MIntroduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening
• 3E0C728Introduction of Oxazolidinones into Eye, Via Natural or Artificial Opening
• 3E0C729Introduction of Other Anti-infective into Eye, Via Natural or Artificial Opening
• 3E0C73ZIntroduction of Anti-inflammatory into Eye, Via Natural or Artificial Opening
• 3E0C7BZIntroduction of Anesthetic Agent into Eye, Via Natural or Artificial Opening
• 3E0C7GCIntroduction of Other Therapeutic Substance into Eye, Via Natural or Artificial Opening
• 3E0C7HZIntroduction of Radioactive Substance into Eye, Via Natural or Artificial Opening
• 3E0C7KZIntroduction of Other Diagnostic Substance into Eye, Via Natural or Artificial Opening
• 3E0C7MZIntroduction of Pigment into Eye, Via Natural or Artificial Opening
• 3E0C7NZIntroduction of Analgesics, Hypnotics, Sedatives into Eye, Via Natural or Artificial Opening
• 3E0C7SFIntroduction of Other Gas into Eye, Via Natural or Artificial Opening
• 3E0C7TZIntroduction of Destructive Agent into Eye, Via Natural or Artificial Opening
• 3E0CX04Introduction of Liquid Brachytherapy Radioisotope into Eye, External Approach
• 3E0CX05Introduction of Other Antineoplastic into Eye, External Approach
• 3E0CX0MIntroduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach
• 3E0CX28Introduction of Oxazolidinones into Eye, External Approach
• 3E0CX29Introduction of Other Anti-infective into Eye, External Approach
• 3E0CX3ZIntroduction of Anti-inflammatory into Eye, External Approach
• 3E0CXBZIntroduction of Anesthetic Agent into Eye, External Approach
• 3E0CXGCIntroduction of Other Therapeutic Substance into Eye, External Approach
• 3E0CXHZIntroduction of Radioactive Substance into Eye, External Approach
• 3E0CXKZIntroduction of Other Diagnostic Substance into Eye, External Approach
• 3E0CXMZIntroduction of Pigment into Eye, External Approach
• 3E0CXNZIntroduction of Analgesics, Hypnotics, Sedatives into Eye, External Approach
• 3E0CXSFIntroduction of Other Gas into Eye, External Approach
• 3E0CXTZIntroduction of Destructive Agent into Eye, External Approach
• 3E0D304Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Percutaneous Approach
• 3E0D305Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach
• 3E0D30MIntroduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach
• 3E0D328Introduction of Oxazolidinones into Mouth and Pharynx, Percutaneous Approach
• 3E0D329Introduction of Other Anti-infective into Mouth and Pharynx, Percutaneous Approach
• 3E0D33ZIntroduction of Anti-inflammatory into Mouth and Pharynx, Percutaneous Approach
• 3E0D34ZIntroduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Percutaneous Approach
• 3E0D36ZIntroduction of Nutritional Substance into Mouth and Pharynx, Percutaneous Approach
• 3E0D37ZIntroduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Percutaneous Approach
• 3E0D3BZIntroduction of Anesthetic Agent into Mouth and Pharynx, Percutaneous Approach
• 3E0D3GCIntroduction of Other Therapeutic Substance into Mouth and Pharynx, Percutaneous Approach
• 3E0D3HZIntroduction of Radioactive Substance into Mouth and Pharynx, Percutaneous Approach
• 3E0D3KZIntroduction of Other Diagnostic Substance into Mouth and Pharynx, Percutaneous Approach
• 3E0D3NZIntroduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Percutaneous Approach
• 3E0D3RZIntroduction of Antiarrhythmic into Mouth and Pharynx, Percutaneous Approach
• 3E0D3TZIntroduction of Destructive Agent into Mouth and Pharynx, Percutaneous Approach
• 3E0D704Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D705Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D70MIntroduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D728Introduction of Oxazolidinones into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D729Introduction of Other Anti-infective into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D73ZIntroduction of Anti-inflammatory into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D74ZIntroduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D76ZIntroduction of Nutritional Substance into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D77ZIntroduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D7BZIntroduction of Anesthetic Agent into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D7GCIntroduction of Other Therapeutic Substance into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D7HZIntroduction of Radioactive Substance into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D7KZIntroduction of Other Diagnostic Substance into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D7NZIntroduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D7RZIntroduction of Antiarrhythmic into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0D7TZIntroduction of Destructive Agent into Mouth and Pharynx, Via Natural or Artificial Opening
• 3E0DX04Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, External Approach
• 3E0DX05Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach
• 3E0DX0MIntroduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach
• 3E0DX28Introduction of Oxazolidinones into Mouth and Pharynx, External Approach
• 3E0DX29Introduction of Other Anti-infective into Mouth and Pharynx, External Approach
• 3E0DX3ZIntroduction of Anti-inflammatory into Mouth and Pharynx, External Approach
• 3E0DX4ZIntroduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, External Approach
• 3E0DX6ZIntroduction of Nutritional Substance into Mouth and Pharynx, External Approach
• 3E0DX7ZIntroduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, External Approach
• 3E0DXBZIntroduction of Anesthetic Agent into Mouth and Pharynx, External Approach
• 3E0DXGCIntroduction of Other Therapeutic Substance into Mouth and Pharynx, External Approach
• 3E0DXHZIntroduction of Radioactive Substance into Mouth and Pharynx, External Approach
• 3E0DXKZIntroduction of Other Diagnostic Substance into Mouth and Pharynx, External Approach
• 3E0DXNZIntroduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, External Approach
• 3E0DXRZIntroduction of Antiarrhythmic into Mouth and Pharynx, External Approach
• 3E0DXTZIntroduction of Destructive Agent into Mouth and Pharynx, External Approach
• 3E0E304Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Percutaneous Approach
• 3E0E305Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach
• 3E0E30MIntroduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach
• 3E0E328Introduction of Oxazolidinones into Products of Conception, Percutaneous Approach
• 3E0E329Introduction of Other Anti-infective into Products of Conception, Percutaneous Approach
• 3E0E33ZIntroduction of Anti-inflammatory into Products of Conception, Percutaneous Approach
• 3E0E36ZIntroduction of Nutritional Substance into Products of Conception, Percutaneous Approach
• 3E0E37ZIntroduction of Electrolytic and Water Balance Substance into Products of Conception, Percutaneous Approach
• 3E0E3BZIntroduction of Anesthetic Agent into Products of Conception, Percutaneous Approach
• 3E0E3GCIntroduction of Other Therapeutic Substance into Products of Conception, Percutaneous Approach
• 3E0E3HZIntroduction of Radioactive Substance into Products of Conception, Percutaneous Approach
• 3E0E3KZIntroduction of Other Diagnostic Substance into Products of Conception, Percutaneous Approach
• 3E0E3NZIntroduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Percutaneous Approach
• 3E0E3SFIntroduction of Other Gas into Products of Conception, Percutaneous Approach
• 3E0E3TZIntroduction of Destructive Agent into Products of Conception, Percutaneous Approach
• 3E0E4GCIntroduction of Other Therapeutic Substance into Products of Conception, Percutaneous Endoscopic Approach
• 3E0E704Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening
• 3E0E705Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening
• 3E0E70MIntroduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening
• 3E0E728Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening
• 3E0E729Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening
• 3E0E73ZIntroduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening
• 3E0E76ZIntroduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening
• 3E0E77ZIntroduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening
• 3E0E7BZIntroduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening
• 3E0E7GCIntroduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening
• 3E0E7HZIntroduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening
• 3E0E7KZIntroduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening
• 3E0E7NZIntroduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening
• 3E0E7SFIntroduction of Other Gas into Products of Conception, Via Natural or Artificial Opening
• 3E0E7TZIntroduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening